Topic
Hepatocellular Carcinoma (HCC)
Podcasts
Vascular & IR # 682Oct 9, 2026Liquid Embolization Techniques for Treating Hypervascular Tumors
How do you devascularize a hypervascular tumor when the vessels feeding it are too small to catheterize? On this episode of BackTable Podcast, Dr. Kavi Krishnasamy is joined by Dr. Resmi Charalel and Dr. Milan Patel to walk through seven real-world cases where non-adhesive hydrogel liquid embolics made the difference. They break down patient selection, case planning, and how to deploy these agents for safe, efficient devascularization when traditional approaches fall short.
- Vascular & IR # 673Sep 8, 2026
Y90 for Liver-Directed Cancer Treatments: The PROACTIF Study
The key to personalizing Y90 may not just be treating the tumor, but understanding how much radiation a patient can tolerate, where to deliver it, and when to safely push the dose. In this episode of the BackTable Podcast, Drs. Tyler Sandow and Ryan Hickey join host Dr. Kavi Krishnasamy to explore strategies for using Y90 in hepatocellular carcinoma and liver metastases. They combine real-world data from a study of nearly 1,000 patients with insights into methodology and the many variables that influence these procedures.
- Vascular & IR # 660Jul 3, 2026
Techniques & Outcomes of Portal Vein Embolization
How is portal vein embolization (PVE) pushing the boundaries of liver tumor resectability, and what does it take to induce hypertrophy without compromising the remnant liver? In this episode of the BackTable Podcast, interventional radiologist Dr. David Madoff of Yale University joins Dr. Michael Barraza to discuss the pathophysiological rationale, technical considerations, and emerging clinical paradigms of performing PVE to augment the future liver remnant (FLR) prior to resection and reduce the risk of postoperative liver failure.
- Vascular & IR # 659Jun 30, 2026
Combination Therapy for Hepatocellular Carcinoma
How do you safely combine locoregional and systemic therapies to treat hepatocellular carcinoma (HCC) when traditional guidelines suggest your hands are tied? In this episode of the 2026 HCC Creator Weekend™, medical oncologist Dr. Lingling Du (Ochsner Health) and interventional radiologist Dr. Beau Toskich (Mayo Clinic Florida) join Dr. Tyler Sandow to break down patient selection, timing strategies, and the practical application of clinical trial outcomes when integrating Y90 radioembolization and immunotherapy in HCC management.
- Vascular & IR # 657Jun 23, 2026
Advanced Techniques in Y90 Cancer Treatment
What do you do when Y-90 doesn’t deliver the results you expected? In this episode of the 2026 HCC Creator Weekend™, host Dr. Tyler Sandow is joined by Drs. Beau Toskich and Juan Gimenez to discuss the technical challenges and troubleshooting strategies that can make or break a Y-90 radioembolization case. Together, they explore innovative approaches like the PREDATr technique, share tips for reducing complications, and offer guidance on optimizing outcomes for patients with complex liver tumors.
- Vascular & IR # 655Jun 16, 2026
Managing Large Liver Tumors: Strategies & Challenges
How is Y90 radioembolization rewriting the rules for managing large HCC tumors and creating new curative-intent therapeutic pathways where palliation was once deemed the only option? In this episode of the 2026 HCC Creator Weekend™, interventional radiologists Dr. Chris Malone (WashU), Dr. Tyler Sandow (Ochsner Health), and Dr. Beau Toskich (Mayo Clinic Florida) join host Dr. Zach Berman for a case-based discussion on advanced dosimetric strategies and embolization approaches for large and complex HCC lesions.
- Vascular & IR # 653Jun 9, 2026
Radiation Lobectomy Techniques & Downstaging for HCC
How can targeted liver radiation unlock surgical or transplant options for tough hepatocellular carcinoma (HCC) cases? In this episode of the BackTable 2026 HCC Creator Weekend™, host Dr. Kavi Krishnasamy is joined by interventional radiologists Dr. Beau Toskich and Dr. Chris Malone to explore how downstaging and radiation lobectomy with Y90 are creating new surgical and transplant opportunities for patients with limited future liver remnants. They discuss Y90’s role as a “test of time” for tumor biology, strategies to prevent post-hepatectomy liver failure, and the ongoing challenge of recurrence even after R0 resection in cirrhotic livers.
- Vascular & IR # 651Jun 2, 2026
Radioembolization Workflow: Insights & Best Practices
What does it really take to run a high-volume Y90 program that is efficient, scalable, and patient-centered? In this episode of the BackTable 2026 HCC Creator Weekend™, host Dr. Zach Berman is joined by Drs. Nima Kokabi and Kirema Garcia-Reyes to break down the systems, workflows, and strategies that drive successful radioembolization centers. The conversation focuses on overcoming referral and insurance delays, implementing multidisciplinary clinics, and using tools like single-session Y90 and routine post-treatment dosimetry to reduce treatment times and improve outcomes.
- Vascular & IR # 649May 27, 2026
Y90 Radioembolization Dosimetry: Techniques & Challenges
Can the right dosimetry approach turn palliative Y90 into a curative therapy? In this episode of the BackTable 2026 HCC Creator Weekend™, interventional oncologists Dr. Riad Salem, Dr. Nima Kokabi, and Dr. Zach Berman examine modern Y90 dosimetry, from the decline of body-surface-area calculations to newer strategies that tailor treatment intensity to tumor burden, liver reserve, and clinical intent.
- Vascular & IR # 647May 21, 2026
Optimizing Liver Cancer Treatment Through Collaboration
In treating hepatocellular carcinoma (HCC), the hardest question often isn’t which treatment to use, it’s who should lead, when to transition care, and how to keep every specialty aligned. In this App Exclusive episode of the BackTable Podcast, host Dr. Jon Mizrahi is joined by interventional radiologist Dr. Juan Gimenez and transplant surgeon Dr. Ari Cohen, to discuss the structure and evolution of Ochsner Health’s multidisciplinary tumor board. Through real-world cases, they illustrate how IR, hepatology, and transplant surgery collaborate to tailor treatment plans, coordinate transitions of care, and navigate follow-up challenges for complex HCC patients.
Tumor Board # 59May 12, 2026Evolving Treatment Paradigms in Hepatocellular Carcinoma: What's on the Horizon?
With new systemic and liver-directed approaches under investigation, which targets and treatment strategies are most likely to shape HCC care? In this final episode of the BackTable 2026 HCC Creator Weekend™, Drs. Lingling Du, A. Craig Lockhart, and Jon Mizrahi focus on the future of hepatocellular carcinoma beyond established PD-1/CTLA-4 regimens.
- Vascular & IR # 644May 12, 2026
Optimizing Liver Transplant Pathways & Decision-Making
A high-functioning HCC tumor board can turn complex transplant decisions into coordinated treatment plans that account for liver reserve, tumor biology, and evolving biomarkers. In this episode of the BackTable Podcast 2026 HCC Creator Weekend™, abdominal transplant surgeon Dr. Ari Cohen (Ochsner Health) and transplant hepatologist Dr. Neil Mehta (UCSF) join host Dr. Kavi Krishnasamy to map out strategies for effective multidisciplinary treatment and transplantation planning in HCC.
- Vascular & IR # 642May 7, 2026
Exploring CPN & Radiation Segmentectomy in Liver Cancer
Complete pathologic necrosis (CPN) rates above 90%? This week’s BackTable episode from the 2026 HCC Creator Weekend™ is cracking the code on complete tumor kill in hepatocellular carcinoma (HCC) bridging therapy. Host Dr. Kavi Krishnasamy is joined by Dr. Zach Berman and Dr. Beau Toskich to break down the latest multi-center research from COBRAS (Consortium on Bridging Radiation Segementectomy with Glass Microspheres Before Transplant), setting a new standard for bridging therapy that offers actionable strategies to improve outcomes.
- Vascular & IR # 641May 5, 2026
Understanding BCLC Updates & Guidelines
With recent updates to the Barcelona Clinic Liver Classification (BCLC), how should multidisciplinary teams adapt their treatment strategies to accommodate the newest evidence? In this episode of the BackTable Podcast 2026 HCC Creator Weekend™, Dr. Neil Mehta of UCSF and Dr. Riad Salem of Northwestern Medicine join host Dr. Tyler Sandow to explore the complexities of hepatocellular carcinoma (HCC) therapies and the practical application of the latest global algorithms in balancing standardized therapeutic algorithms with individual patient factors.
- Tumor Board # 58May 5, 2026
Advanced Hepatocellular Carcinoma: Navigating Second-Line Therapy Options
When first-line treatment for advanced hepatocellular carcinoma (HCC) fails and the disease progresses, what options are available for second-line therapy? In this episode of the BackTable 2026 HCC Creator Weekend™, Drs. Lingling Du, A. Craig Lockhart, and Jon Mizrahi explore the uncertain landscape of second-line treatment after first-line immunotherapy, such as atezolizumab and bevacizumab or the STRIDE regimen, including practical considerations for choosing which second-line therapy to use.
- Vascular & IR # 640May 1, 2026
Hepatic Arteriography & C-Arm CT-Guided Liver Ablation
When a liver tumor is hard to see, the limits of conventional image guidance can become the limits of treatment. In this episode of the BackTable Podcast, Netherlands interventional oncologist Dr. Maarten (M.L.J.) Smits shares a step-by-step walkthrough of the new hepatic arteriography and C-arm CT–guided ablation (HepACAGA) technique, punctuated with a real-world case series at the end. Find out how intra-arterial contrast, cone-beam CT, and 3D needle guidance can improve tumor conspicuity, targeting accuracy, and ablation margin assessment within a single angiography suite.
- Vascular & IR # 639Apr 30, 2026
Advancements in Ablation Techniques for Liver Tumors
Why settle for “good enough” ablation margins when today’s tools can deliver more and decrease the risk of recurrence? Host Dr. Kavi Krishnasamy sits down with interventional radiologists Dr. Christopher Malone (WashU, St. Louis) and Dr. Kirema Garcia-Reyes (Mount Sinai, NYC) at our 2026 HCC Creator Weekend™ in-studio in New Orleans to discuss modern liver ablation strategies for HCC and metastatic disease. The conversation centers on challenging real-world cases, combining multidisciplinary tumor board insights with hands-on experience using ablation confirmation software, radiofrequency, cryo, and microwave ablation.
- Tumor Board # 57Apr 28, 2026
First-Line Therapy for Advanced Hepatocellular Carcinoma: Decisions in the Real World
Learn how a “watershed” clinical trial in 2020 completely overturned a decade of standard care for liver cancer. In this inaugural episode of the BackTable 2026 HCC Creator Weekend™ , medical oncologists Dr. John Rahi, Dr. Craig Lockhart, and Dr. Lingling Du review the evolution of first-line systemic therapy for hepatocellular carcinoma (HCC), highlighting immune checkpoint inhibitors as a major change from the TKI era.
- Vascular & IR # 632Apr 8, 2026
Career Choices That Work & Those That Don't Work
You may know him as the godfather of Y90, but you might not know what it took for Dr. Riad Salem to earn that title. Curiosity, ambition, critical thinking. High highs and devastating losses. This episode offers an inside look at how intellectual curiosity and patient focus fuel innovation in interventional radiology, featuring the man himself and hosts Dr. Tyler Sandow and Dr. Juan Gimenez in-studio in New Orleans.
- Vascular & IR # 577Sep 30, 2025
Microwave Ablation for Liver Tumors: Techniques & Outcomes
Is microwave ablation only for simple liver tumors, or can it be a versatile ‘Swiss Army knife’ for a wide range of complex cases? In this episode, Dr. Driss Raissi of the University of Kentucky returns to BackTable to join host Dr. Chris Beck for a deep dive into advanced and unconventional microwave ablation techniques. They cover strategies for tackling a wide range of cases, from desmoid tumors to enterocutaneous fistulas.
- Vascular & IR # 564Aug 12, 2025
Pressure-Enabled Drug Delivery in HCC & Metastatic Liver Lesions
Can you manipulate blood flow in the tumor microenvironment to optimize drug delivery? In this episode of the BackTable Podcast, interventional oncologist Dr. Zachary Berman (UC San Diego) joins host Dr. Christopher Beck to discuss real-world applications of pressure-enabled drug delivery in local, regional liver-directed therapies like TACE and Y90.
- Vascular & IR # 561Jul 29, 2025
Dosimetry University VI: Challenging Case Review
When is Y90 the right treatment for metastatic disease? Join Drs. Tyler Sandow, Zach Berman and host Kavi Krishnasamy in the conclusion of Dosimetry University where they discuss the complexities of treating different variations of metastatic disease and review how they’ve approached complicated cases with Y90.
- Vascular & IR # 559Jul 22, 2025
Dosimetry University V: Case Review on Dose Optimization Strategies
The balance between targeting tumor and sparing healthy liver is delicate. How do the experts do it? In this case-based review, Drs. Zach Berman (UC San Diego) and Tyler Sandow (Ochsner Health) join host Dr. Kavi Krishnasamy to walk us through real-world scenarios and share how they approach Y90 dose optimization.
- Vascular & IR # 556Jul 8, 2025
Dosimetry University Part IV: Optimizing Radiation Segmentectomy
Radiation segmentectomy: who, when, how? Interventional oncologists Dr. Nima Kokabi, Dr. Tyler Sandow, and Dr. Kavi Krishnasamy continue their in-studio discussion on all things Y90 in Part 4 of Dosimetry University, focusing on specific applications of radiation segmentectomy.